Livagen Dosage, half-life & reference guide
Also known as Lys-Glu-Asp-Ala · KEDA peptide · Lyvagen
Reviewed Evidence: EmergingPublished by PepVault
A four-amino-acid peptide from the Russian bioregulator program behind Epitalon, which its developers describe as a bioregulator for the liver. In rat liver cells it raised protein synthesis, most in cells from old animals, and in old rats it moved digestive enzymes toward young levels; in lymphocytes from old people it switched silenced genes back on. No human study has been published.
- How often
- Daily
- Half-life
- Unknown
- Evidence
- ●
●●Emerging - Routes
- SubQ, Oral capsules
No human study has tested a dose of Livagen: the amounts people run are their own protocol, not a reference.
How it works.
A tetrapeptide, Lys-Glu-Asp-Ala (KEDA), that Vladimir Khavinson's St. Petersburg group built from the amino acids of their liver peptide preparations and describe as the liver's bioregulator. In cultured liver cells from rats it raised protein synthesis, most in cells from old animals; given by mouth to rats for two weeks, it moved the digestive enzymes of old rats toward young levels. In lymphocytes from old people grown in the lab it loosened tightly packed chromatin, which its developers read as switching silenced genes back on, and in human serum it blocked the enzymes that break down enkephalins, the body's own opioid peptides. No human study of Livagen is indexed on PubMed.
Commonly reported: Little to feel during a course; user reports are few.

Where Livagen works.

Gut
In animals. In rats, two weeks of Livagen by mouth moved the digestive enzymes of old animals toward those of young ones.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- Not established (no human data)
- Peak effect
- Not established
- Duration
- Courses of 10–20 days (community practice)
Day 1–14Community
A quiet course
Livagen has no human studies, and users who share their runs mostly report little to feel. Commonly reported: mild discomfort where it goes in, or an unsettled stomach with capsules.
Updated Nov 2026
Day 14–60Animal
What the rat studies measured
In rats, two weeks of Livagen by mouth moved the digestive enzymes of old animals toward those of young ones, and in rat liver cells it raised protein synthesis, most in cells from old animals. Neither has been tested in people.
The science
Timofeeva 2005: Livagen is barely hydrolysed by small-intestine peptidases; after two weeks by mouth, digestive enzyme activity fell in young rats and rose in old ones, toward young controls. Brodsky 2001: in monolayer cultures of hepatocytes from rats aged 1–24 months, it raised protein synthesis, most in cells from old rats, while Epitalon did not change it.
Sources- Timofeeva et al. (2005)
- Brodsky et al. (2001)
Updated Nov 2026
Any dayAnimal
What Livagen is built on
A four-amino-acid peptide from the Russian bioregulator program, built from the make-up of liver peptide extracts. Its evidence is rat studies and lab work on rat liver cells and human blood cells, almost all by its developers; there is no human study.
The science
Brodsky 2001: KEDA was obtained by directed synthesis from the amino-acid analysis of liver polypeptide preparations. Khavinson 2002: in lymphocytes from old people it activated ribosomal genes and decondensed pericentromeric heterochromatin. Kost 2003: in human serum it inhibited enkephalin-degrading enzymes (IC50 20 µM, Epitalon 500 µM) and did not bind mu or delta opioid receptors of rat brain. Kuznik 2020 reviews its liver work in animals and cells with the calf-liver complex it was built from.
Sources- Brodsky et al. (2001)
- Khavinson et al. (2002)
- Kost et al. (2003)
- Timofeeva et al. (2005)
- Kuznik et al. (2020)
Updated Nov 2026
With EpitalonAnimal
Two bioregulators, two organs
If you run Epitalon too: the two were tested side by side in the same lab studies and acted differently, Livagen raising protein synthesis in liver cells where Epitalon didn't. No study has given them together, in animals or people.
The science
Brodsky 2001: Livagen raised hepatocyte protein synthesis; Epitalon did not change it. Kost 2003: both inhibited serum enkephalinases, Livagen about 25 times more strongly by IC50.
Sources- Brodsky et al. (2001)
- Kost et al. (2003)
Updated Nov 2026
Day 1 is the day you start it.
No human study of Livagen has been published. The effects come from rat studies and lab work on rat and human cells, almost all by its developers.
Preliminary research
A typical run.
Run notes
- Cycle
- Run in short courses rather than continuously, like the other bioregulators: community courses run about 10–20 days, a few times a year. In the rat study it was given by mouth for two weeks. No study in people has tested a course length.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- No timing has been studied. Small intestine enzymes barely break it down, which is the basis for taking it by mouth.
- Routes
- SubQ injection, Oral capsules
- Stacks
- Pinealon
Safety.
Common side effects
- Injection-site discomfort
- Mild stomach upset (capsules)
Interactions
No interaction studies exist. In human serum in the lab it blocked the enzymes that break down enkephalins, so opioid medicines are worth raising with your clinician.
Safety notes
No safety study exists: no human study of Livagen is indexed, so its side effects are known only from user reports, and nothing is known about long-term use. Discuss with your clinician before use, particularly during pregnancy or breastfeeding, or with a liver condition.
Goes with.
One question at a time.
Compared with.
Questions people ask.
What is Livagen?
A four-amino-acid peptide from the Russian bioregulator program behind Epitalon, which its developers describe as a bioregulator for the liver. In rat liver cells it raised protein synthesis, most in cells from old animals, and in old rats it moved digestive enzymes toward young levels; in lymphocytes from old people it switched silenced genes back on. No human study has been published.
How is Livagen dosed in research?
The library carries no reference dose for Livagen. No human study has tested a dose of Livagen: the amounts people run are their own protocol, not a reference.
How long does Livagen last?
The half-life of Livagen is unknown (never measured).
What do people report on Livagen?
Commonly reported on Livagen: little to feel during a course; user reports are few.
Is Livagen safe?
The research basis for Livagen is emerging: primarily preclinical / limited human data. Common side effects in the library: injection-site discomfort and mild stomach upset (capsules).
What does Livagen stack with?
Common stacks for Livagen: Pinealon.
Research.
Reference.
- Cadence
Daily
- Half-life
Unknown
Unknown (never measured)
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
Reviewed How we check the library
